Nineteen-year single-center experience in 76 patients with penile cancer treated with high-dose-rate brachytherapy
| Autor: | Karolina Trzaska, Zofia Kołosza, Dawid Larysz, Marcin Wesolowski, Agnieszka Cholewka, Sylwia Kellas-Ślęczka, Piotr Wojcieszek, Brygida Białas, Marta Szlag, Maciej Ślęczka, Tomasz Krzysztofiak, Agnieszka Pruefer, Marek Fijałkowski |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Brachytherapy Urethral stenosis Single Center 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine medicine Carcinoma Humans Penile cancer Radiology Nuclear Medicine and imaging Treatment Failure Penile Neoplasms Aged Aged 80 and over Salvage Therapy business.industry Middle Aged medicine.disease High-Dose Rate Brachytherapy Surgery Survival Rate Persistent Disease medicine.anatomical_structure Oncology Lymphatic Metastasis 030220 oncology & carcinogenesis Dose Fractionation Radiation Neoplasm Recurrence Local business Organ Sparing Treatments Penis |
| Zdroj: | Brachytherapy. 18:493-502 |
| ISSN: | 1538-4721 |
| Popis: | PURPOSE To report the outcomes for 76 patients with penile cancer treated with high-dose-rate brachytherapy (HDR-BT) at a single institution. METHODS Seventy-six patients with penile cancer treated with HDR-BT in our department between October 1998 and September 2018 were analyzed. Seventy underwent interstitial HDR-BT (fractionation dose range of 3–3.5 Gy given twice a day with an interval of at least six hours between the fractions), and six underwent superficial treatment with mold applicators (fractionation dose range of 4–7 Gy given once or twice a week). RESULTS Median follow-up was 76 months (7–204 months). In the whole group, 22/76 local failures (28.9%) were observed: 14/76 (18.4%) local recurrences and 8/76 (10.5%) cases of persistent disease. Median time to recurrence was 24 months (9–54 months). Inguinal lymph node metastases were observed in 18/76 cases (23.7%). Distant metastases occurred in 12/76 (15.8%) cases. Patients with local recurrence and persistent disease underwent salvage penectomies, except four who refused surgery and underwent a second course of interstitial HDR-BT. Five- and 10-year cause-specific survival were 85.0% and 77.8%, respectively. Local control at 5 and 10 years was 65.6%. Five- and 10-year penile preservation were 69.5% and 66.9%, respectively. There was no G3 or G4 acute toxicity. One urethral stenosis (1.3%) occurred in a patient with a T3 tumor and was treated successfully with dilatation. CONCLUSIONS HDR-BT provides good local control of penile cancer and is a good option for penis preservation therapy and in our experience achieves a penile preservation rate at 10 years of 66.9%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|